Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. - Common Stock (NQ:HELP)

6.810 +0.330 (+5.09%)
Streaming Delayed Price Updated: 3:33 PM EDT, Jun 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,417,839
Open 6.660
Bid (Size) 6.810 (1,000)
Ask (Size) 6.830 (500)
Prev. Close 6.480
Today's Range 6.550 - 6.890
52wk Range 3.760 - 8.970
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal 2026 Results, Highlights Phase 3 Progress
Via Investor Brand Network
News headline image
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
From Helus Pharma
Via GlobeNewswire

Performance

YTD
-11.9%
-11.9%
1 Month
+49.7%
+49.7%
3 Month
+57.6%
+57.6%
6 Month
-11.9%
-11.9%
1 Year
-11.9%
-11.9%

More News

Read More
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Closes $50 Million Public Offering
Via Investor Brand Network
News headline image
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Prices $50 Million Public Offering
Via Investor Brand Network
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Surpasses 86% Enrollment in Phase 3 APPROACH Trial
Via Investor Brand Network
News headline image
FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
Via FinancialNewsMedia
News headline image
Helus Pharma™ Announces US$50 Million Underwritten Offering
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
From Helus Pharma
Via GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Chief Medical Officer to Participate in H.C. Wainwright Neuro Perspectives Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Jefferies Global Healthcare Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Issues Correction To TARA Mind Partnership Announcement
Via Investor Brand Network
News headline image
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
From Helus Pharma
Via GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Partners With TARA Mind to Support Phase 3 Trial Recruitment in Veterans
Via Investor Brand Network
News headline image
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Adds Robert Langer, Stephen Brannan To Scientific Advisory Board
Via Investor Brand Network
News headline image
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks –  Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Supports Executive Order Advancing Psychedelic Therapies
Via Investor Brand Network
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO Steps Down, Eric So Named Interim Chief Executive Office
Via Investor Brand Network
News headline image
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
From Helus Pharma
Via GlobeNewswire
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Ken Kramer SVP Medical Affairs
Via Investor Brand Network

Frequently Asked Questions

Is Cybin Inc. - Common Stock publicly traded?
Yes, Cybin Inc. - Common Stock is publicly traded.
What exchange does Cybin Inc. - Common Stock trade on?
Cybin Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cybin Inc. - Common Stock?
The ticker symbol for Cybin Inc. - Common Stock is HELP on the Nasdaq Stock Market
What is the current price of Cybin Inc. - Common Stock?
The current price of Cybin Inc. - Common Stock is 6.810
When was Cybin Inc. - Common Stock last traded?
The last trade of Cybin Inc. - Common Stock was at 06/29/26 03:33 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.